Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study

Aim: To evaluate the satisfaction, preferences and adherence of patients in secondary cardiovascular prevention treated with the CNIC cardiovascular polypill compared with patients treated with the separate monocomponents. Methods: Observational, cross-sectional and multicenter study. Satisfaction w...

Descripción completa

Detalles Bibliográficos
Autores: Cosin-Sales, J, Murcia-Zaragoza, JM, Pereyra-Rico, HO, de la Guia-Galipienso, F, Hermans, K, Rubio, G
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10733
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/10733
Access Level:acceso abierto
Palabra clave:adherence
cardiovascular
polypill
preferences
prevention
satisfaction
Descripción
Sumario:Aim: To evaluate the satisfaction, preferences and adherence of patients in secondary cardiovascular prevention treated with the CNIC cardiovascular polypill compared with patients treated with the separate monocomponents. Methods: Observational, cross-sectional and multicenter study. Satisfaction was evaluated by the Treatment Satisfaction Questionnaire for Medication 9 items, adherence by the Morisky-Green questionnaire and ad-hoc questions were asked regarding patient preferences. Results: Polypill patients reported higher satisfaction than patients treated with the monocomponents (77.3 vs 71.2%, p < 0.0001). 72.8% of patients treated with the monocomponents would prefer to change to the polypill. Patients treated with the polypill had significantly higher adherence than patients treated with the monocomponents (57.7 vs 41.1%) (p = 0.0027). Conclusion: Polypill patients show higher satisfaction and better adherence. Most patients receiving the monocomponents would prefer a polypill regime.